Javier Muñoz

19.6k citations

133 papers · 1.8k indexed · 1 hit paper · h-index 23

Impact in

Genetics top 2%
- Chronic Lymphocytic Leukemia Research
- Virus-based gene therapy research
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment

Papers in

Genetics 47
- Chronic Lymphocytic Leukemia Research 47
Pathology and Forensic Medicine 75
- Lymphoma Diagnosis and Treatment 74

Co-authors: Razelle Kurzrock Filip Jankú Sattva S. Neelapu Stephen Opat Constantine S. Tam Olalekan O. Oluwole Julio C. Chávez Ellen Schlette
Journals: Blood (33 papers)Journal of Clinical Oncology (29 papers)Hematological Oncology (8 papers)Transplantation and Cellular Therapy (5 papers)Blood Advances (4 papers)
Partner nations: United States France Australia

In The Last Decade

Javier Muñoz

124 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial 2022 · 186 citations

Peers

Countries citing papers authored by Javier Muñoz

Since Specialization

Citations

This map shows the geographic impact of Javier Muñoz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Muñoz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Muñoz more than expected).

Fields of papers citing papers by Javier Muñoz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Muñoz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Muñoz. The network helps show where Javier Muñoz may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Javier Muñoz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Javier Muñoz Line = papers co-authored together Javier Muñoz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Clinical Qualification of Subcutaneous Injection Devices for Monoclonal Antibodies BioDrugs ·Beate Bittner, Javier Muñoz, Sabine Frank, Michael Dolton, Gyarfas Wj, Markus Dembowski, Mikhailova Li, W. Richter	2025	0
2	Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies Journal of Clinical Oncology ·Frederick L. Locke, Javier Muñoz, Michael Tees, Lazaros J. Lekakis, Sven de Vos, Rajneesh Nath, Don A. Stevens, Shahbaz A. Malik, Geoffrey Shouse, Mehdi Hamadani, Olalekan O. Oluwole, Miguel‐Angel Perales, David B. Miklos, P.W. Fisher, Amy Feng, Lynn Navale, Christophe Boussemart, Sattva S. Neelapu	2025	11
3	Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study Blood ·Julio C. Chávez, Michael Dickinson, Javier Muñoz, Matthew L. Ulrickson, Catherine Thiéblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, B. Ashtir, Peter A. Riedell, Natasha Kekre, Sven de Vos, Jacob Wulff, Иван Иванович Дончев, Joshua D. Winters, Ioana Kloos, Hairong Xu, Sattva S. Neelapu	2025	3
4	Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7 Blood Advances ·Armin Ghobadi, Javier Muñoz, Jason R. Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel‐Angel Perales, Patrick M. Reagan, Joseph P. McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Rong-hua Yuan, Marco Schupp, Christina To, Olalekan O. Oluwole	2024	4
5	Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL Cancer Treatment Reviews ·Javier Muñoz, Anagha Deshpande, Lisa M. Rimsza, Grzegorz S. Nowakowski, Razelle Kurzrock	2024	5
6	Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study Blood ·Jacqueline Wang, Jihao Zhou, Nadine Ilunga, Han W. Tun, Javier Muñoz, Jonas Paludo, Muhamad Alhaj Moustafa, Steven R. Hwang, Noelia Soriano Conesa, Catherine Diefenbach, Jia Ruan, Peter Martin, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang	2024	0
7	Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma. Journal of Clinical Oncology ·Yucai Wang, Melissa C. Larson, Anita Kumar, Brian T. Hill, David A. Bond, Brad S. Kahl, Alexey V. Danilov, Reid W. Merryman, Natalie S. Grover, Aung M. Tun, Sabarish Ayyappan, Georgios Pongas, Craig A. Portell, Javier Muñoz, Patrick M. Reagan, Muhamad Alhaj Moustafa, Priyanka A. Pophali, Irl Brian Greenwell, Jonathon B. Cohen, Peter Martin	2024	1
8	Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality Blood Advances ·Kai Rejeski, Yucai Wang, Doris K. Hansen, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Müller, Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Bücklein, Pere Barba, Frederick L. Locke, B. Ashtir, Michael D. Jain, Marion Subklewe	2024	29
9	If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide Med ·Jacob J. Adashek, Javier Muñoz, Razelle Kurzrock	2024	3
10	Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma Blood ·Marc Hoffmann, Theodoros P. Vassilakopoulos, Javier Muñoz, Jason R. Westin, Maria Bouzani, Wojciech Jurczak, Michał Kwiatek, Yury A. Kholopov, Tai‐Chung Huang, 義人望月, В.М. Девишвили, Dmytro Pavlenko, 伸彦弓崎, Grzegorz S. Nowakowski	2024	1
11	CODOX-M/IVAC-R <i>versus</i> DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under Haematologica ·Suheil Albert Atallah‐Yunes, Wing‐Keung Cheung, Thomas E. Witzig, Thomas M. Habermann, Javier Muñoz, Madiha Iqbal, Ellen D. McPhail, Grzegorz S. Nowakowski	2024	0
12	Incorporating radiation with anti‐CD19 chimeric antigen receptor T‐cell therapy for relapsed/refractory non‐Hodgkin lymphoma: A multicenter consensus approach American Journal of Hematology ·Omran Saifi, Scott C. Lester, William G. Breen, William G. Rule, Yi Lin, N. Nora Bennani, Allison Rosenthal, Javier Muñoz, Hemant S. Murthy, Mohamed A. Kharfan‐Dabaja, Jennifer Peterson, Bradford S. Hoppe	2023	9
13	Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality Blood ·Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, S. Karunanidhi, Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe	2023	1
14	The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL American Journal of Hematology ·Kai Rejeski, Yucai Wang, Omar Albanyan, Javier Muñoz, Pierre Sesques, Gloria Iacoboni, Lucía López‐Corral, Al Nyhart, Veit Bücklein, Razan Mohty, Martin Dreyling, Aliyah Baluch, Bijal Shah, Frederick L. Locke, Georg Heß, Pere Barba, Emmanuel Bachy, Yi Lin, Marion Subklewe, Michael D. Jain	2023	17
15	Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma Transplantation and Cellular Therapy ·Javier Muñoz, Ian W. Flinn, Jonathon B. Cohen, Jessica Sachs, Mituru Uyama, Ann Ranger, 葛颖倩, Francis Payumo, Rajneesh Nath, Mehdi Hamadani, Jason R. Westin, Veronika Bachanová	2023	2
16	Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy Transplantation and Cellular Therapy ·Madiha Iqbal, Radhika Bansal, 仇晓锋, Alejandro García Garnica, Allison Rosenthal, Muhamad Alhaj Moustafa, Zhuo Li, Taijiro Yonera, Razan Mohty, Hemant S. Murthy, Ernesto Ayala, Han W. Tun, Javier Muñoz, Januario E. Castro, Yi Lin, Mohamed A. Kharfan‐Dabaja	2022	5
17	Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy Current Treatment Options in Oncology ·Shannon P. Fortin Ensign, S. Gottschalk, Tommaso Fabbri, Michael W. Ruff, Eveliina Tuovinen, A. Serrafero, Januario E. Castro, Javier Muñoz, Allison Rosenthal, Maciej M. Mrugała	2022	6
18	Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma Blood ·Tycel Phillips, Adam J. Olszewski, Javier Muñoz, Tae Min Kim, Dok Hyun Yoon, Richard Greil, Jason R. Westin, Ulrich Jaeger, Miguel Canales, Cindy Chen, Betsy Althaus, Carol O’Hear, Ahlam Salih Eltahir, Yuying Xie, Ronald McCord, Enkhtsetseg Purev, みゆき泉澤	2020	37
19	PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111) HemaSphere ·Judith Trotman, Stephen Opat, Paula Marlton, David Gottlieb, David Simpson, Gavin Cull, David Ritchie, Emma Verner, Javier Muñoz, Alessandra Tedeschi, Jennifer J. Huang, William Novotny, Medhat Osman, Siminder Atwal, John F. Seymour, Andrew W. Roberts, Constantine S. Tam	2019	3
20	Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation Journal of Clinical Oncology ·Javier Muñoz, Ellen Schlette, Razelle Kurzrock	2013	53

About Javier Muñoz

Javier Muñoz is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Dermatology and Immunology, having authored 133 papers that have together received 1.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (74 papers), CAR-T cell therapy research (65 papers), Chronic Lymphocytic Leukemia Research (47 papers), Chronic Myeloid Leukemia Treatments (12 papers), Biosimilars and Bioanalytical Methods (12 papers), Cutaneous lymphoproliferative disorders research (11 papers), Integrated Circuits and Semiconductor Failure Analysis (10 papers) and Viral-associated cancers and disorders (8 papers). The work is most often cited by research in Genetics (545 citations), Pathology and Forensic Medicine (886 citations), Oncology (1.2k citations), Immunology (333 citations) and Hematology (154 citations). Javier Muñoz has collaborated with scholars based in United States, France and Australia. Frequent co-authors include Razelle Kurzrock, Filip Jankú, Sattva S. Neelapu, Stephen Opat, Constantine S. Tam, Olalekan O. Oluwole, Julio C. Chávez, Ellen Schlette, Sven de Vos and Gavin Cull. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, Transplantation and Cellular Therapy and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact